Towards evidence based medicine for paediatricians

Edited by Bob Phillips

In order to give the best care to patients and families, paediatricians need to integrate the highest quality scientific evidence with clinical expertise and the opinions of the family. Archimedes seeks to assist practising clinicians by providing “evidence based” answers to common questions which are not at the forefront of research but are at the core of practice.

A word of warning. The topic summaries are not systematic reviews, though they are as exhaustive as a practising clinician can produce. They make no attempt to statistically aggregate the data, nor search the grey, unpublished literature. What Archimedes offers is practical, best evidence based answers to practical, clinical questions.

The format of Archimedes may be familiar. A description of the clinical setting is followed by a structured clinical question. (These aid in focusing the mind, assisting searching, and gaining answers.) A brief report of the search used follows—this has been performed in a hierarchical way, to search for the best quality evidence to answer the question. A table provides a summary of the evidence and key points of the critical appraisal. For further information on critical appraisal, and the measures of effect (such as number needed to treat, NNT), books by Sackett et al and Moyer et al may help. To pull the information together, a commentary is provided. But to make it all much more accessible, the clinical bottom line is highlighted.

Readers wishing to submit their own questions—with best evidence answers—are encouraged to read the Instructions for Authors at http://www.archdischild.com

Critical appraisal note: evidence of equivalence versus no evidence of difference

When a randomised study compares two therapies and finds no difference in an important outcome between the two, does this provide evidence of equivalence or merely an absence of evidence of effectiveness? The practical answer requires integration of the study with clinical expertise.

If a dichotomous outcome is present (dead versus not, hospitalised versus sent home) then a variety of measures can be generated. Of these, those which give information of the risk reduction (relative, absolute, or its inverse; the number needed to treat) are useful. With continuous outcome measures, estimates of difference can also be produced, but may be more difficult to interpret. A confidence interval can be produced for each of these measures, within whose limits the true effect is likely to fall. This degree of uncertainty is the first element to be considered in the question. As a rule of thumb, if a study cannot exclude a 20% difference between the treatments, it is probably not evidence of equivalence.

The second element requires knowledge of the disease and outcome. If the outcome is fatal, disfiguring or had serious morbidity, perhaps a greater degree of certainty is required. There is also the rest of the clinical literature on the subject—does this result agree with the general tenor of evidence or does it stick out?

Combining these aspects—precision, importance, and congruence—allows an answer to the question of equivalence versus lack of difference.

Evidence-based On Call, Cairns Library, John Radcliffe Hospital, Oxford OX3 9DU, UK

Correspondence to: Bob Phillips
bob.phillips@doctors.org.uk

www.archdischild.com
Are routine chest x rays helpful in the management of febrile neutropenia?

**Scenario**

A friendly, coryzal 5 year old girl with acute lymphocytic leukemia attends with another episode of febrile neutropenia. According to departmental protocol, her admission includes a chest x ray. You wonder as to the value of this routine irradiation.

**Structured clinical question**

In a 5 year old girl with febrile neutropenia [patient] does routine chest radiography [intervention] assist in management decisions or diagnose occult pneumonia [outcome]?

**Search**

Secondary sources—nil.

SumSearch—“neutropenia” AND “radiography” AND filter “diagnosis”.

Search results—67 individual articles found, three relevant.

**Summary**

See table 1.

**Commentary**

There is no good quality study addressing the use of chest radiographs in uncomplicated febrile neutropenia. Two of these studies are consistent with clinical feeling—lack of abnormal signs or symptoms in children with febrile neutropenia rules out pneumonia. The methodological weaknesses would tend to favour this—with one study having clinical features as part of the reference standard, and the second tending to fail to perform chest radiography on children without symptoms. The third study only gives data on respiratory signs (ignoring symptoms) and has a subsequently reduced sensitivity and improved specificity.

---

**Clinical bottom line**

- Pneumonia was uncommon in children with febrile neutropenia (<3%).
- An absence of respiratory signs and symptoms made pneumonia very unlikely.
- Routine chest x rays seem unnecessary.

**Authors**

Clare Collins (Research Fellow, Oxford Vaccine Group, Oxford) [clare.collins@paediatrics.ox.ac.uk]
Matthew Fenton (Registrar in Paediatric Oncology, John Radcliffe Hospital, Oxford)
Bob Phillips (Junior Fellow, Centre for Evidence-based Medicine)


---

**Table 1**

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study group</th>
<th>Study type (level of evidence)</th>
<th>Outcome</th>
<th>Key results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feusner et al (1988)</td>
<td>64 patients with 134 episodes of febrile neutropenia</td>
<td>Prospective cohort (4)</td>
<td>Prevalence of “infectious&quot; infiltrates</td>
<td>3.0% (95% CI 0.81% to 7.7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diagnostic usefulness of &quot;tachypnoea, chest pain or abnormal auscultation&quot;</td>
<td>LR+ 82 (95% CI 11 to 575) LR− 0.0 (95% CI 0.0 to 0.19)</td>
<td></td>
</tr>
<tr>
<td>Korones et al (1997)</td>
<td>54 patients with 108 episodes of febrile neutropenia</td>
<td>Prospective cohort (4)</td>
<td>Prevalence of pneumonia</td>
<td>3.7% (95% CI 0.14% to 7.2%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diagnostic usefulness of &quot;abnormal auscultatory findings, RR&gt;20 when afebrile or O2 sats &lt;95% twice in 4 hours&quot;</td>
<td>LR+ 17.3 (95% CI 7.9 to 38) LR− 0 (95% CI 0 to 0.79)</td>
<td></td>
</tr>
<tr>
<td>Katz et al (1998)</td>
<td>131 patients with febrile neutropenia</td>
<td>Prospective cohort (4)</td>
<td>Prevalence of pneumonia</td>
<td>3.1% (95% CI 0.7% to 7.8%)</td>
<td>Only 128/131 patients received a chest radiograph</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diagnostic usefulness of presence of respiratory signs</td>
<td>LR+ infinite (lower 95% CI 0.00) LR− 0.5 (95% CI 0.25 to 1.0)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Does dexamethasone improve blood pressure in hypotensive ill neonates?**

**Scenario**

A 25 week gestation baby, birth weight 695 g is ventilated for respiratory distress syndrome. Invasive blood pressure monitoring at 2 hours of age showed a mean of 23–25 mm Hg. The blood pressure did not improve over the next 24 hours, in spite of three intravenous boluses of 0.9% saline and concurrent infusions of dopamine and dobutamine at 15 µg/kg/min.

A colleague suggests that dexamethasone might help to improve the baby’s blood pressure.

**Structured clinical question**

In hypotensive preterm infants [patient] does treatment with dexamethasone [intervention] increase blood pressure [outcome]?

**Search**

Secondary sources—nil.

Search strategy—“hypotension” AND “(dexamethasone OR steroid)” AND “newborn” AND “(clinical trial)”. Search results—three articles found, two relevant.

**Summary**

See table 2.
Commentary

The study by Gassmaier and Weston was well constructed in terms of randomisation, blinding, and intention to treat analysis. Dexamethasone administration, after treatment with volume boluses, dopamine, and adrenaline infusion, improved BP such that adrenaline was discontinued in 63% babies (compared with 11% of placebo group).

The paper by Bourchier and Weston supports the idea that bolus steroids are a useful adjunct to conventional treatments for hypotension in sick, ventilated preterm infants. Dopamine and hydrocortisone both appeared to be effective (p = 0.108) in the treatment of hypotension refractory to treatment with fluid bolus. However, if five babies received hydrocortisone, one additional baby remained hypotensive, compared with similar babies who received dopamine. Confidence intervals for this NNT are wide (3, 45), suggesting a larger study would show statistical difference at the 5% level.

Dexamethasone appears to be a useful adjunct to the commonly used pathway for treating hypotension in neonates (fluid bolus ± dopamine ± dobutamine). Although no adverse events related to steroid use are reported in either paper, no long term follow up is reported and caution is warranted as there is emerging evidence of increased risk of cerebral palsy, following postnatal dexamethasone use in babies at risk for chronic lung disease (Shinwell et al, Arch Dis Child Fetal Neonatal Ed 2000;83:F177–F181), without improvement in mortality (Halliday and Ehrenkranz. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews, Issue 1, 2001).

Clinical bottom line

- Dexamethasone improved blood pressure in ill, ventilated neonates.

Author

Richard Nicholl (Consultant Neonatologist) [DrNicholl@aol.com] on behalf of The Northwick Park Neonatal Journal Club, Northwest London NHS Hospitals Trust


Table 2

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study group</th>
<th>Study type (level of evidence)</th>
<th>Outcome</th>
<th>Key results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gassmaier and Weston (1999)</td>
<td>20 preterm babies (mean body wt 690 g), hypotensive in spite of volume support and inotropes</td>
<td>Randomised, double blind, placebo controlled trial (1b)</td>
<td>Discontinuation of adrenaline at 12 hours</td>
<td>Absolute risk reduction (ARR) for withdrawal of adrenaline was 52% and NNT = 2 (95% CI 1 to 8)</td>
<td>All blood pressure readings measured invasively</td>
</tr>
<tr>
<td>Bourchier and Weston (1997)</td>
<td>40 hypotensive preterm babies</td>
<td>Randomised, open trial of hydrocortisone ± dopamine (1b)</td>
<td>Hypotension despite treatment: dopamine: 0/19; hydrocortisone: 4/21</td>
<td>Absolute risk increase (ARI) was 20% for hydrocortisone and NNH = 5 (95% CI 3 to 45)</td>
<td>Method of BP measurement not stated in this paper</td>
</tr>
</tbody>
</table>

Does nebulised adrenaline reduce admission rate in bronchiolitis?

Scenario

A 4 month old infant attends the emergency department in the late morning with bronchiolitis. It is the first episode of wheeze. Clinically, there is moderate indrawing and recession, tachypnoea (RR = 50), reasonable air movement on auscultation, and the oxygen saturation is 94% in air. You want to admit the infant, but the mother is breast feeding and keen to get home by 3 pm, when her other children get home from school. You have heard that in North America, nebulised adrenaline has been used in some cases and admission has been avoided.

Structured clinical question

In an infant with bronchiolitis [patient] does nebulised adrenaline (compared to other treatments) [intervention] reduce the need for admission [outcome]?

Search

Secondary sources—Cochrane Library (2001): “bronchiolitis”, two systematic reviews (one irrelevant—anticholinergics and wheeze); Clinical Evidence (Issue 4): “child health—bronchiolitis”, two systematic reviews (one irrelevant—adrenaline not included); DARE: “bronchiolitis”, five systematic reviews (three irrelevant; two relevant SRs were by same authors—one referenced in Cochrane and one referenced in journal).

PubMed clinical queries: “bronchiolitis” AND “epinephrine” [therapy, sensitive]—eight references (three irrelevant to question).

MedLine [1966 to Dec 2000] (Ovid): “bronchiolitis” OR “bronchitis” AND “[epinephrine (exp)]” OR “catecholamines”]; LIMIT to “clinical trial”—13 references (eight irrelevant to question).

Five papers addressed the question of nebulised adrenaline and bronchiolitis (one of them specifically answering the question).

Summary

See table 3.

Commentary

There is only one study (Menon et al) that specifically answers the question; this study shows a reduction in hospital admission, and the study group is similar to the patient in the clinical scenario.
A systematic review that includes adrenaline as one of a number of bronchodilators fails to show significant differences in outcomes compared to placebo. However, adrenaline has an α adrenergic action which is thought to be important in bronchiolitis (as well as the β adrenergic bronchodilatory effects it has). The positive effect of adrenaline may therefore have been diluted in the systematic review by the inclusion of agents that have little or no effect.

The Menon et al study compared adrenaline with salbutamol, which is not routinely used in the UK in this condition. For this reason, data on studies comparing adrenaline to placebo in bronchiolitis are also presented. Studies comparing the two show a benefit of adrenaline over placebo as well as benefit over pure β adrenergic agonists.

It is thought that the α adrenergic properties of adrenaline are important in bronchiolitis, as the vasoconstriction of the pulmonary vessels reduces mucosal oedema and exudate, thereby reducing airway obstruction.

The regime used was 3 ml of 1/1000 adrenaline nebulated at arrival and 30 minutes later. The infants were then observed for at least two hours.

Currently, a multicentre trial in the UK comparing nebulised adrenaline with placebo is under discussion.

**Clinical bottom line**
- Nebulised adrenaline probably reduced hospital admission in bronchiolitis
- Nebulised adrenaline appeared superior to salbutamol and placebo in relieving symptoms in bronchiolitis.

**Table 3**

<table>
<thead>
<tr>
<th>Citation</th>
<th>Study group</th>
<th>Study type</th>
<th>Outcome</th>
<th>Key results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kellner et al (1996)</td>
<td>Wheeze &lt;24 months. Looking at a range of bronchodilators (incl adrenaline) compared to placebo</td>
<td>Systematic review—most studies double blind RCTs (level 1a)</td>
<td>Clinical score</td>
<td>Slight improvement in bronchodilator group; RR = 0.76 (95% CI 0.6 to 0.95) May have seen a slight improvement because of inclusion of recurrent wheezers</td>
<td></td>
</tr>
<tr>
<td>Menon et al (1995)</td>
<td>42 first time wheezers less than 12 months. Nebulised adrenaline cf nebulised salbutamol</td>
<td>Double blind RCT (level 1b)</td>
<td>Hospital admission</td>
<td>No difference; RR = 0.85 (95% CI 0.47 to 1.53)</td>
<td>Small study</td>
</tr>
<tr>
<td>Reijonen et al (1995)</td>
<td>100 consecutive wheezers less than 24 months admitted. Compared adrenaline, salbutamol and placebo (N saline)</td>
<td>Double blind RCT (level 1b)</td>
<td>Oxygen saturation</td>
<td>Significantly higher in adrenaline group at 1 h (96% vs 94%) Included some recurrent wheezers</td>
<td></td>
</tr>
<tr>
<td>Kristjansson et al (1993)</td>
<td>29 infants (&lt;18 months) with acute bronchiolitis. Adrenaline cf placebo</td>
<td>Double blind RCT (level 1b)</td>
<td>Symptom score</td>
<td>Significant improvement with adrenaline Both groups included recurrent wheezers</td>
<td></td>
</tr>
<tr>
<td>Sanchez et al (1993)</td>
<td>24 infants &lt;1 y, with first episode of bronchiolitis. Adrenaline cf salbutamol</td>
<td>Double blind crossover RCT (level 1b)</td>
<td>Clinical score</td>
<td>Significant improvement with adrenaline cf salbutamol; NNT = 4 (95% CI 3 to 7) Significant improvement with adrenaline cf salbutamol</td>
<td>Mean age 4.6 months (±0.5). Patients sedated with chloral hydrate</td>
</tr>
</tbody>
</table>

**Author**

Maud Meates (Consultant Paediatrician, North Middlesex Hospital, London) [mmeates@doctors.org.uk]
Towards evidence based medicine for paediatricians

Arch Dis Child 2001 85: 252-255
doi: 10.1136/adc.85.3.252

Updated information and services can be found at:
http://adc.bmj.com/content/85/3/252

These include:

Supplementary Material
Supplementary material can be found at:
http://adc.bmj.com/content/suppl/2001/09/05/85.3.252.DC1
http://adc.bmj.com/content/suppl/2003/02/14/85.3.252.DC2

References
This article cites 12 articles, 3 of which you can access for free at:
http://adc.bmj.com/content/85/3/252#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/86/6/455.2.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiologic studies (1818)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Acrodynia: a case report of two siblings

Acrodynia, a rare disorder, is a form of chronic mercury poisoning. 1 We report two siblings who developed the classic clinical picture of acrodynia.

A 4½ year old boy was admitted with dysuria, general weakness, and loss of appetite. He had hypertension (140/95 mm Hg) and tachycardia (141 beats/min). He was irritable and depressed, and had a diffuse itching papular rash with palmar erythema and superficial desquamation. 2 Initial evaluation revealed a normal complete blood count and a normal blood chemistry. Urine analysis and complement levels were normal. Vanillylmandelic acid in a 24 hour urine collection was 22.2 µmol/L. Duplex scan of the renal arteries, abdominal ultrasound, and computerised tomography (CT) of the chest and abdomen, were all normal. Heart echocardiography showed mild hypertrophy of the myocardium. TSH was 5.53 mU/L, and free thyroxine 24.45 pmol/L. A brain CT scan revealed a point calcification at the right caudate nucleus and several bilateral areas of low density in the white matter. EEG was normal. A successive complete blood count revealed haemocoencentration (haemoglobin 165 g/l and haematocrìt 48.1%).

After eight days, the patient's 6 year old brother was admitted with general weakness, pain in his lower extremities, and a diffuse itching papular rash with palmar erythema and superficial desquamation. He was hypertensive (126/87 mm Hg) and tachycardic (140 beats/min).

Due to the fact that both siblings presented, at the same time, with more or less the same complaints and physical findings, it was suspected that their condition may have been the result of an environmental exposure. It was discovered that three months previously, the family had travelled to a remote part of the country where mercury poisoning had been diagnosed, and the baby had been treated with a compound containing mercury. Three months later, the baby had relapsed.

The differential diagnosis included Acrodynia and other causes of generalized skin rash, such as pityriasis rosea and atopic dermatitis. The differential diagnosis also included a variety of viral and bacterial infections, such as measles, rubella, parvovirus, and pertussis.

The patient was admitted and treated with oxygen and erythromycin. After 12 hours she developed respiratory failure (respiratory rate 100 breaths/min, pH 7.16, pCO2 74 mm Hg, pO2 17 mm Hg, HCO3 36, base excess -3) and was transferred to the paediatric intensive care unit with intubation and pressure control (peak inspiratory pressure 22, peak end expiratory pressure 3, FiO2 0.35, respiratory rate 40). Twenty four hours later, hypoxaemia necessitated increasing FiO2 to 1, and refractory hypotension required volume load and inotropics (TAM 38). Echocardiography diagnosed severe lung hypertension (pulmonary artery pressure 65 mm Hg) and decreased heart contractility. Nitric oxide 8 ppm and milrinone 0.37 µg/kg/min temporarily improved pO2, but this subsequently deteriorated (pO2 40 mm Hg). High frequency ventilatory therapy was initiated; nitric oxide up to 20 ppm was given, and inotropic support enhanced, but with no response. She suffered a fatal cardiac arrest 98 hours later. The family did not authorise necropsy.

Fatal myocardial failure secondary to lung hypertension has been reported in four infants under 2 months with verified B pertussis infection. 3 All presented with initial tachycardia (160-230 beats/min) refractory to treatment with volume load, and developed posterior persistent hypotension that did not respond to inotropic support. Lung vasodilators such as nitric oxide, milrinone, or prostacycline may be useful in management of these patients, although they did not prove beneficial in our patient.

Because of the rapid deterioration of all these cases, we recommend early echocardiography diagnosis, enabling vasodilator treatment with volume load, and developed posterior persistent hypotension that did not respond to inotropic support. Lung vasodilators such as nitric oxide, milrinone, or prostacycline may be useful in management of these patients, although they did not prove beneficial in our patient.

References


Bordetella pertussis infection causing pulmonary hypertension

In Spain the incidence of whooping cough is less than five cases per 100 000 inhabitants. 1 Mortality rate is 0.4% in the United States, heart failure being one of the most frequent causes. 2 Although cases of death due to Bordetella pertussis infection as a consequence of lung hypertension have been described previously, 3 this complication is not very well known. Here we report a recent case and review the literature.

A 23 day old girl, who had had a pertussis cough for several days, was admitted with breathing difficulty of 12 hours duration. On admission she had tachycardia (heart rate 180 beats/min), tachypnoea (70 breaths/min), pyrexia (38°C), and haemoglobin saturation 90% without oxygen. A chest x ray revealed right superior and half lobe infiltrates. Blood analysis showed 33 × 10⁹ leucocytes with left deviation and 33 mg/dl C reactive protein. Testing for respiratory syncitial virus was negative; direct immunofluorescence and culture for B pertussis were both positive.

The patient was admitted and treated with oxygen and erythromycin. After 12 hours she developed respiratory failure (respiratory rate 100 breaths/min, pH 7.16, pCO₂ 74 mm Hg, pO₂ 17 mm Hg, HCO₃ 36, base excess -3) and was transferred to the paediatric intensive care unit with intubation and pressure control (peak inspiratory pressure 22, peak end expiratory pressure 3, FiO₂ 0.35, respiratory rate 40). Twenty four hours later, hypoxaemia necessitated increasing FiO₂ to 1, and refractory hypotension required volume load and inotropics (TAM 38). Echocardiography diagnosed severe lung hypertension (pulmonary artery pressure 65 mm Hg) and decreased heart contractility. Nitric oxide 8 ppm and milrinone 0.37 µg/kg/min temporarily improved pO₂, but this subsequently deteriorated (pO₂ 40 mm Hg). High frequency ventilatory therapy was initiated; nitric oxide up to 20 ppm was given, and inotropic support enhanced, but with no response. She suffered a fatal cardiac arrest 98 hours later. The family did not authorise necropsy.

Fatal myocardial failure secondary to lung hypertension has been reported in four infants under 2 months with verified B pertussis infection. 3 All presented with initial tachycardia (160-230 beats/min) refractory to treatment with volume load, and developed posterior persistent hypotension that did not respond to inotropic support. Lung vasodilators such as nitric oxide, milrinone, or prostacycline may be useful in management of these patients, although they did not prove beneficial in our patient.
therapy to be initiated in the early phase of lung hypertension in order to improve prognosis.

P Casano, M Pons Odena, F J Cambram, J M Martin, A Palomque
Hospital Sant Joan de Déu, Unidad de Cuidados Intensivos Pediátricos, Passeig de Sant Joan de Déu, 2 08095, Esplugues de Llobregat, Barcelona, Spain; mpions@hsjdc.org

References


BOOK REVIEWS

Management for Child Health Services


Children’s services have increasing priority with the present government in the UK. If we are to use available resources wisely and provide the “seamless service” that children and their parents deserve, then we need good managers to oversee their delivery. Who are these people and where are they found? The editors of this book believe that “all involved in child health care are, by definition, involved in its management”—so that none of us is excluded—and that “they should have the benefit of material drawn together specifically for this purpose”—material which they have sought to provide.

For me, much of this book was virgin territory, and I found it a good, readable introduction, and an information resource upon which I will draw in the future. Those with more experience would also find it useful. It is in no way a reference text book, but contributors from child health, legal, and management fields bring their experience together to cover the many different aspects involved in managing a service. Useful references are supplied at the end of each chapter for those who wish to delve further. The first chapter comprises a brief historical review of child health services during the twentieth century, and one realizes the degree of expansion from small and inauspicious beginnings. Later chapters are devoted to such topics as management skills, models of service quality, audit, finance, risk control, and management. Issues around the partnership of care with parents and carers are explored, and interagency working—never easy to carry out in practice—forms the basis of another chapter. Peculiarly interesting and informative chapter was written as a case study of the establishment and running of an integrated secondary level child health service. Another chapter, which was perhaps a little easier reading, discussed legal and ethical principles relevant to child health using a hypothetical, if perhaps slightly artificial, family case history of a baby born with significant disability to a single mother who is also facing adolescent health issues in her teenage daughter. The final section is devoted to the services in the four countries comprising the UK, each with unique values and approaches, although built upon a common base.

As child health services and service plans continue to evolve, there is much we can learn from the experience of those who have been involved in establishing our present services—we must avoid their pitfalls and follow their successes. The book was written before the most recent service changes involving the establishment of Primary Care Trusts, and one can only speculate whether what a revised version will contain after “the next 10 years”. Will we, the present day paediatricians, leave a similar legacy for our successors?

R J Jefferson

Sudden infant death syndrome: problems, progress and possibilities


As an internationally recognised disease classification, sudden infant death syndrome (SIDS) is unique in that the diagnosis is reached by exclusion, by failing to demonstrate an adequate cause of death. By definition it is imprecise, the diagnosis of SIDS depends on the thoroughness of the post-mortem examination, the extent of detail given in the clinical history and the meticulous nature with which the death scene investigation is carried out. Even if these conditions are satisfied to some chosen specification, this is not an end point but a rather a beginning, as we are still left with the question of “why did these babies die?”

The tragedy of SIDS is not a modern phenomenon but was only christened a syndrome 40 years ago and, after extensive research, the possibility of finding a collection of symptoms and signs manifesting as a single cause appears extremely unlikely. Some experts suggest a triple risk causal mechanism for SIDS involving a vulnerable infant, a critical development period and an exogenous event that would not normally put a healthy child at risk. A particular group, frustrated with what they see as a definition of convenience, want to restrict the liberal use of such a diagnosis to exclude suspected cases of accidental suffocation and infanticide. Hypotheses continue to proliferate and, as the evidence for risk factors mount, the debate has widened from causation to the relative safety of accepted infant care practices.

In trying to understand how infants die, we have come to the realisation that we must first understand how infants survive. SIDS research has developed from basic epidemiological and pathological findings at death to a wider investigation of infant sleep structure, care practices, physiology, and genetics. This multidisciplinary approach is elegantly illustrated in Byard and Krouse’s book. The eclectic choice of contributing experts gives a clear insight into current thinking and recent discoveries in different fields, while challenging the reader with a subtle consensus of disagreement. The book gives detailed background of each debate but is more than a reference manual for other researchers in the field. Given the rarity of SIDS, many medical professionals may not have been involved with the sudden death of a child but will have to deal with mothers concerned about child safety, while some parents are reticent to accept advice unless they know how this has been derived, this book is also for them.

If there appears to be a lack of co-ordination in the approach among different research groups, a slightly over zealous interpretation of findings by some experts and perhaps more confusion than clarity in the overall picture, then this book has given a true reflection of SIDS research as it currently stands. There is no ending to the story because infants still die suddenly and unexpectedly, but if SIDS research is to be ultimately judged on its number of young lives so far saved then the endeavours of those involved should be highly commended.

P S Blair

Child Abuse and Neglect, A Clinician’s handbook. 2nd edn.


Coming back to the new edition of this book is like coming back to an old friend. Like many paediatricians, I have used the first edition as a valuable reference in child protection cases. The expertise and experience of all three authors are well recognised internationally and there is no doubt that this edition will continue to be a valuable aid to all clinicians working with children.

All aspects of abuse are covered and there are helpful summaries in each chapter. It is an easy book to read but also I find it easy to get information on individual issues in child protection. There is an interesting historical introduction: although I would have liked rather more before modern times.

The problem I find with this book is that it is not really evidence based in a modern sense. Papers are quoted with no real attempt to assess their quality. This is partially because there are so few quantitative studies in child protection but I think readers would have liked to have more descriptions on the quality of the methodology of the papers that are quoted. I would have liked the references tabulated in each area of abuse. There are also concerns regarding the section on epidemiology of abuse. The histogram that is used as an illustration does not give incidence rates nor is it population based.

I particularly studied areas in the book that I know cause diagnostic difficulty and where there is controversy. One of these is subdural haemorrhage. I was disappointed that the section was quite short: only four pages. I was also disappointed at the number of references, only 14, in what is the most common cause of serious physical harm in physical child abuse.
I find that neglect and emotional abuse are areas where it is difficult to put facts together for a clear diagnosis. The section on neglect has a helpful list of points to look for in the potentially neglected child and also ways of assessing the whole family. I found the section on emotional abuse less helpful.

Child protection is a very difficult area for clinicians and many shy away from committing themselves to clear diagnoses. This new edition will help give more confidence in dealing with these difficult cases. It is a pity that at nearly £70 it will not be accessible to young doctors outside libraries. Perhaps fewer photographs and being in paperback would make it less expensive and more accessible.

J R Sibert

**Mosby’s atlas and text of pediatrics and child health**


I enjoyed reviewing this book aimed at students and doctors in training, and I also learned from it. I must add that it is a good source of information for doctors who are preparing for examinations.

The book gives useful information, is highly illustrated and the format with text boxes and lists levels itself for easy reading and reference (revision for examinations). The photographs are well placed with the text and with excellent explanations, which accompany the photographs, x rays, and scans. The quality of the photographs are superb too, thus the clinical phenotypes, which the authors want to illustrate are clearly visible. I found the book easy to read and understand.

I am sure that this book will prove very useful and will fill the gap in the market, as it will attract those adult learners who learn visually. It lends itself for scan reading for revision.

I teach examination preparation courses and I will bring this book to the attention of candidates sitting the DCH and MRCPCH exams. I would think that the GP tutors who come across this book would find it helpful in their teaching too. Many of the illustrations and slides will enhance anyone’s teaching methods.

More books like this are needed in paediatrics and child health as the pictures and illustrations that the doctors see will enhance their learning (and retention) skills. With problem orientated teaching (and learning) that we now practise, this type of book and presentations would be a most welcome addition. The market is not saturated, and I hope it will never be.

S Lingam

CORRECTION

Unfortunately the authors for the items in the Archimedes articles for September and November 2001 were not correctly coded and do not show up using searches on ADC Online or Medline. The authors for these articles should be cited as follows:

**September**


**November**

